Chemotherapy and cancer drugs
The latest chemistry news and research on chemotherapy and cancer drugs, including antibodies and immuno-oncology, from the Royal Society of Chemistry's magazine, Chemistry World
-
NewsFears grow over the future of mRNA vaccine research in the US
Researchers working on mRNA vaccines fear federal funding might be halted, with many looking to move projects abroad
-
FeatureThe promise of drugs that send proteins to the shredder
Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to strategic discovery
-
ResearchAI tool learns to build molecules fragment by fragment
Software tasked with designing a type-II kinase inhibitor suggests 97 candidates in 10 minutes, three of which were both synthesisable and effective at micromolar and nanomolar concentrations
-
WebinarEmerging routes to new therapeutics: Highlights from winning Horizon Prize teams
Discover how new therapeutics have the potential to address unmet medical needs
-
WebinarThe science and promise of liquid biopsies: improving cancer treatment
Learn how liquid biopsies are being used to identify cancer and improve patient outcomes
-
FeatureThe high price of a suntan
Skin cancer is on the rise in many countries around the world, but so are the methods to treat it. Bárbara Pinho reports
-
BusinessPan-cancer approval shows huge potential for antibody–drug conjugates
Enhertu gains approval based on gene expression rather than tumour location
-
BusinessBig deals confirm renewed interest in radiopharmaceuticals
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
-
FeatureMore than a mirror-image: left-handed nucleic acids
Now a biological reality, researchers are starting to figure out the many roles of left-handed nucleic acids such as Z-DNA – from immunity to controlling our genetics. Rachel Brazil reports
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
BusinessPfizer to buy cancer biotech Seagen for $43 billion
Antibody-drug conjugate specialist will fill Pfizer’s cancer pipeline
-
ResearchAlphaFold works with other AI tools to go from target to hit molecule in 30 days
End-to-end AI drug discovery process predicts potential inhibitors for a protein implicated in liver cancer
-
ResearchRadium chelator researchers working to improve targeted cancer therapies
Oak Ridge National Lab team investigate factors underpinnning Ra2+ complex stability and selectivity in attempt to expand the therapeutic utility of radium-223
-
ResearchYeast engineered to ferment sugars into chemotherapy drug precursors
Semisynthesis offers new route to anticancer drug vinblastine
-
ResearchLight-activated cancer treatment uses tumour-targeting enzymes to cut side effects
Enzymatic activation of a photosensitive prodrug in cancerous cells shows promise in mice
-
BusinessMorphosys agrees to buy cancer epigenetics specialist Constellation
$1.7bn deal will be funded by selling rights to royalties on existing drugs
-
ResearchClick chemistry uses endogenous acrolein to activate cancer prodrug
Strategy could reduce chemotherapy side effects by selecting for cancerous cells
-
BusinessAntibody–drug conjugates drive growth in oncology
Antibody–drug conjugates are coming of age and pharma is investing, reports Katrina Megget
-
ResearchNanoparticle can starve aggressive breast cancer cells of vital copper
A new engineered particle depletes copper from mitochondria, killing breast cancer cells in mice
-
ResearchIntroducing chirality to give organic electronics a twist
Medicinal molecules and electronic materials aren’t often found in the same research group. Meet Matthew Fuchter, who’s excelling at both